We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

WEX:NYSEWEX Inc. Analysis

Data as of 2026-05-10 - not real-time

$141.64

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

WEX posted a 5.8% year‑over‑year revenue increase to $673.8 million in Q1 2026 and delivered non‑GAAP EPS of $4.15, slightly beating consensus, while its full‑year revenue guidance of $2.85 billion sits 1.5% above analysts’ estimates. Operating margins remain robust at 23.5% and gross margins above 72%, supporting a strong cash conversion profile with free cash flow exceeding $1.2 billion. However, the stock slid 16% after the earnings release, and technical indicators are mixed: the MACD is bearish, the RSI sits at 36 (near oversold), and volume is trending down, suggesting short‑term pressure. The current price of $141.64 is far below the DCF‑derived fair value of $623, implying an upside potential of roughly 28% and an analyst consensus “Buy” rating with a median target near $176. With a beta around 1.0 and 30‑day volatility over 60%, the equity carries heightened market risk, but its high ROE (~30%) and strong balance sheet (cash > $5.4 billion, debt‑to‑equity > 400% driven by leveraged growth) provide a solid foundation for a rebound. The support level at $138 and resistance near $187 frame the near‑term trading range, while the extreme‑greed market sentiment (FGI 90.7) adds a bullish backdrop. Overall, the fundamentals are compelling, yet the near‑term technical weakness and liquidity concerns temper immediate enthusiasm.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Bearish MACD and decreasing volume indicate near‑term downside pressure
  • Price is near support at $138, limiting downside risk
  • Recent 16% earnings‑driven sell‑off creates a potential entry point

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • Fundamentals show strong revenue growth and high profitability margins
  • DCF fair value suggests ~28% upside and analyst median target around $176
  • Robust cash generation and low dividend reliance support reinvestment

Long Term

> 3 years
Positive
Model confidence: 9/10

Key Factors

  • Sustained high ROE and expanding SaaS platform across payments and benefits
  • Strategic partnerships (e.g., Impactive Capital) broaden addressable market
  • Long‑term valuation gap and industry positioning in high‑growth fintech infrastructure

Key Metrics & Analysis

Financial Health

Revenue Growth5.80%
Profit Margin11.50%
P/E Ratio16.0
ROE29.77%
ROA2.87%
Debt/Equity410.95
P/B Ratio3.9
Op. Cash Flow$605.1M
Free Cash Flow$1.3B
Industry P/E38.4

Technical Analysis

TrendNeutral
RSI36.4
Support$137.96
Resistance$186.86
MA 20$159.41
MA 50$157.88
MA 200$158.01
MACDBearish
VolumeDecreasing
Fear & Greed Index90.73

Valuation

Fair Value$623.27
Target Price$181.20
Upside/Downside27.93%
GradeUndervalued
TypeGrowth

Risk Assessment

Beta1.07
Volatility64.36%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.